Exelixis
EXEL
#1710
Rank
NZ$21.45 B
Marketcap
NZ$85.37
Share price
1.01%
Change (1 day)
18.70%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of May 2026 (TTM): 5.31

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.83. At the end of 2026 the company had a P/S ratio of 4.69.

P/S ratio history for Exelixis from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20264.69-7.3%
20255.0613.58%
20244.459.22%
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
5.85 10.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.33-56.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
4.92-7.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
1.91-64.03%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
4.60-13.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.50-52.80%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
2.33-56.01%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
1.68-68.40%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
5.53 4.19%๐Ÿ‡บ๐Ÿ‡ธ USA